The Japanese Catheter Ablation Registry (J‐AB): Annual report in 2019

investigators, J‐Ab registry

doi:10.1002/joa3.12640

Cited by 9 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We think this because vascular complications are infrequent in a nationwide registry of non-ESKD patients, where BARC ≥2 bleeding complications occurred in 1.12%. 25 This figure is substantially smaller than that of the present cohort, where we observed BARC ≥2 bleeding in 12%. The order of magnitude greater rate of puncture site bleeding in our cohort compared to non-ESKD counterparts cannot be due to differences in the use of ultrasound-guided puncture.…”

Section: Discussioncontrasting

confidence: 77%

Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry

et al. 2023

View full text Add to dashboard Cite

Aims The optimal anticoagulation regimen in patients with end-stage kidney disease (ESKD) undergoing atrial fibrillation (AF) catheter ablation is unknown. We sought to describe the real-world practice of peri-procedural anticoagulation management in patients with ESKD undergoing AF ablation. Methods and results Patients with ESKD on haemodialysis undergoing catheter ablation for AF in 12 referral centres in Japan were included. The international normalized ratio (INR) before and 1 and 3 months after ablation was collected. Peri-procedural major haemorrhagic events as defined by the International Society on Thrombosis and Haemostasis, as well as thromboembolic events, were adjudicated. A total of 347 procedures in 307 patients (67 ±9 years, 40% female) were included. Overall, INR values were grossly subtherapeutic [1.58 (interquartile range: 1.20–2.00) before ablation, 1.54 (1.22–2.02) at 1 month, and 1.22 (1.01–1.71) at 3 months]. Thirty-five patients (10%) suffered major complications, the majority of which was major bleeding (19 patients; 5.4%), including 11 cardiac tamponade (3.2%). There were two peri-procedural deaths (0.6%), both related to bleeding events. A pre-procedural INR value of 2.0 or higher was the only independent predictor of major bleeding [odds ratio, 3.3 (1.2–8.7), P = 0.018]. No cerebral or systemic thromboembolism occurred. Conclusion Despite most patients with ESKD undergoing AF ablation showing undertreatment with warfarin, major bleeding events are common while thromboembolic events are rare.

show abstract

Section: Discussioncontrasting

confidence: 77%

Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The incidence in our study was on the low end of that range (0.3% and 0.2%, respectively) and was similar to that reported in the Japanese Catheter Ablation registry (0.64% and 0.14%, respectively). 10 Given that there was no oral anticoagulant-related bleeding in the present study, anticoagulants appeared to be well controlled. Taken together, our findings demonstrate a favourable safety profile for VS-guided AF ablation in Japanese patients.…”

Section: Discussionmentioning

confidence: 64%

Acute and mid-term outcomes of ablation for atrial fibrillation with VISITAG SURPOINT: the Japan MIYABI registry

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background and Aims The effectiveness of pulmonary vein isolation (PVI) guided by VISITAG SURPOINT (VS) has been demonstrated in Western populations. However, data for Asian populations are limited. VS settings may differ for Asians, given their smaller body size. This study aimed to describe outcomes of radiofrequency atrial fibrillation (AF) ablation guided by VS in a large Asian population. Methods The prospective, observational, multicenter MIYABI registry collected real-world data from patients undergoing VS-guided AF ablation using Thermocool SmartTouch and Thermocool SmartTouch SF catheters from 50 Japanese centers. All patients had paroxysmal AF or persistent AF for <6 months. Primary adverse events (PAEs) were evaluated for safety. The primary efficacy endpoint was the proportion of patients with PVI at the end of the procedure. Mid-term effectiveness (up to 12 months) was evaluated by freedom from documented atrial arrhythmias. Results Of the 1011 patients enrolled, 1002 completed AF ablation. The mean number of VS values per procedure was 428.8 on the anterior wall and 400.4 on the posterior wall. Nine patients (0.9%) experienced PAEs. Upon procedure completion, 99.7% of patients had PVI. Twelve-month freedom from atrial arrhythmia recurrence was 88.5%; 5.7% of patients were re-ablated. At repeat ablation, 54% of RSPV, 73% of RIPV, 70% of LSPV, and 86% of LIPV evaluated remained durably isolated. Conclusion Despite lower anterior wall VS values compared with the CLOSE protocol (≥550), the present study demonstrated comparable efficacy outcomes, indicating that a VS of ≥550 for the anterior wall may not be necessary for Asian patients.

show abstract

“…11 The PVS patients in our cohort were 10 years younger than Japanese AF ablation patients reported in The Japanese Catheter Ablation Registry (mean [±SD] age 67±11 years). 2 In addition, based on the left atrial diameter evaluated by transthoracic echocardiography, the left atrial remodeling in our cohort was less advanced than that in general AF ablation cases. 13-15 PVS after AF ablation has been reported, even in pediatric cases.…”

Section: Mechanism Of Pvs After Af Ablationmentioning

confidence: 58%

Pulmonary Vein Intervention for Severe Pulmonary Vein Stenosis After Atrial Fibrillation Ablation　― A Retrospective Cohort Study ―

Yokoi,

Katsuki,

Yamaguchi

et al. 2024

Circ J

View full text Add to dashboard Cite

outcomes, to help establish optimal diagnostic and treatment procedures for this iatrogenic complication. Methods Study PatientsThis multicenter retrospective observational study was conducted at 3 cardiovascular centers in Japan (Saga University Hospital, Kokura Memorial Hospital, and Sagaken Medical Centre Koseikan). Thirty patients who were clinically indicated to undergo PV intervention for PVS or PV occlusion after AF ablation between 2010 and 2023 were enrolled in the study. Thirty paients with 56 lesions in 43 PV interventional procedures were analyzed retrospectively. PVS was defined as >75% stenosis or total occlusion evaluated by contrast-enhanced computed tomography (CT). The clinical indications for PV intervention were D ue to the aging population in Japan, the number of patients with atrial fibrillation (AF) is increasing rapidly. 1,2 Catheter ablation, mainly pulmonary vein (PV) isolation, is actively performed to maintain sinus rhythm. 3,4 However, severe PV stenosis has been reported (frequency 0.5-4.0%) as a serious complication of catheter ablation in the chronic phase, and can be fatal if not treated appropriately. 5-8 Percutaneous PV intervention is a treatment option for PV stenosis (PVS), but the diagnostic and treatment procedures have not yet been established due to the limited number of reported cases in Japan. 9 The number of catheter ablation cases in Japan is increasing every year, 2 and PV intervention for PVS is predicted to increase in the future. The aim of the present study was to investigate and describe data on PV intervention for PVS from a multicenter registry, including patient background, interventional procedures, and long-term

show abstract

The Japanese Catheter Ablation Registry (J‐AB): Annual report in 2019

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 9 publications

References 5 publications

Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry

Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry

Acute and mid-term outcomes of ablation for atrial fibrillation with VISITAG SURPOINT: the Japan MIYABI registry

Pulmonary Vein Intervention for Severe Pulmonary Vein Stenosis After Atrial Fibrillation Ablation　― A Retrospective Cohort Study ―

Contact Info

Product

Resources

About

The Japanese Catheter Ablation Registry (J‐AB): Annual report in 2019

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 9 publications

References 5 publications

Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry

Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease–atrial fibrillation ablation registry

Acute and mid-term outcomes of ablation for atrial fibrillation with VISITAG SURPOINT: the Japan MIYABI registry

Pulmonary Vein Intervention for Severe Pulmonary Vein Stenosis After Atrial Fibrillation Ablation ― A Retrospective Cohort Study ―

Contact Info

Product

Resources

About

Pulmonary Vein Intervention for Severe Pulmonary Vein Stenosis After Atrial Fibrillation Ablation　― A Retrospective Cohort Study ―